肝细胞癌
医学
免疫疗法
肿瘤科
癌症
阶段(地层学)
内科学
古生物学
生物
作者
Maria Tagliamonte,Angela Mauriello,Beatrice Cavalluzzo,Concetta Ragone,Carmen Manolio,Annacarmen Petrizzo,Franco M. Buonaguro
标识
DOI:10.1016/j.canlet.2019.12.029
摘要
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease. Nevertheless, HCC is considered an immunogenic tumor arising in chronically inflamed livers. In such a scenario, immunotherapy strategies for HCC, in particular combinations including cancer vaccines, may represent a key therapeutic tool to improve clinical outcome in HCC patients. However, a lot of improvement is needed given the disappointing results obtained so far.
科研通智能强力驱动
Strongly Powered by AbleSci AI